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1. Introduction 
The main aim of the chapter entitled Management Approaches to Congenital Adrenal 
Hyperplasia (CAH) in Adolescents and Adults; Latest Therapeutic Developments, will be 
first to familiarize readers with current treatment guidelines using glucocorticoid and 
mineralocorticoid replacement in treating this common and under-diagnosed cause of 
amenorrhea. Next, to introduce readers to the concept of insulin resistance in CAH and 
treatment approaches based upon increasing insulin sensitivity. Finally, we shall consider 
possible future directions in the treatment of CAH. 
2. Current conventional therapy for congenital adrenal hyperplasia 
2.1 Glucocorticoid replacement: Rationale, current dosing considerations and 
benefits 
Conventional therapy for this family of disorders with glucocorticoids and sometimes 
mineralocorticoid remains, for now, the gold standard. The rationale for this approach is 
straightforward and logical. CAH is a family of disorders in which there are mutations in one 
or more genes for enzymes involved in adrenal (and sometimes ovarian) steroidogenesis, 
rendering the resultant enzyme less functional than the wild type. Alternatively, there is no 
mutation in the region coding for the enzyme, but one may be found, for example, in the 
promoter region affecting either gene expression or enzyme activity (Trapp et al., 2011). 
In each of these situations the hypothalamic-pituitary-adrenal (HPA) axis goes into overdrive 
due to negative feed-back attempting to produce adequate levels of cortisol and sometimes 
aldosterone. When aldosterone synthesis is also impaired the renin-angiotensin aldosterone 
system (RAAS) likewise goes into overdrive (Merke & Bornstein, 2005; White, 1997). 
The presence of partial blocks in the biosynthesis of cortisol and/or aldosterone results in the 
diversion of a portion of adrenal steroidogenesis into the available unblocked pathway, 
androgen synthesis. Androgen synthesis is further stimulated by the enhanced activities of 
the HPA and the RAAS (White, 1997). 
For the most part, this strategy of providing the adrenocortical end-products, glucoco-
rticoids and mineralocorticoids, is spectacularly successful. Instituted in the nursery this 
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therapy will prevent severe salt wasting, dehydration and death in infants born with severe, 
salt-wasting forms of classical CAH. It prevents most progression of virilization and 
prepares the infant for corrective external genital surgery, if required. Begun early enough it 
will usually result in gender identity which is congruent with the child’s chromosomal sex 
(Raff, 2004; Young & Hughes, 1990).  
Treatment principles for adolescent and adult patients are quite similar to those used in 
treating adrenal insufficiency. Total daily maintenance doses of hydrocortisone range from 
15 to 30 mg, of cortisone acetate from 12.5 to 37.5 mg and of prednisone from 3 to 5 mg. 
Dexamethasone is generally avoided because of difficulty of titration at low doses, long half 
life, resulting in overlap of daily doses, and its lack of any effect on the mineralocorticoid 
receptor (Speiser et al., 2010; Merke, 2008).  
As with adrenal insufficiency, recommended doses for CAH have fallen by 25-35% over the 
past 10-15 years as better estimates of normal daily cortisol production have become 
available. With the adoption of lower doses of glucocorticoid it is anticipated that there will 
be a lower future prevalence of bone loss, hyperglycemia, capillary fragility, and other 
complications of long term glucocorticoid use (Speiser et al., 2010). 
In adrenal insufficiency glucocorticoid is typically dosed in a way that approximates the 
diurnal rhythm of cortisol secretion e.g. the morning doses of hydrocortisone and cortisone 
acetate are about twice the evening doses; if prednisone is chosen it is usually dosed in the 
morning. In CAH the treatment concept is to suppress the diurnal morning surge in adrenal 
androgen production. Thus, the evening doses of hydrocortisone and cortisone acetate will 
be double of the morning dose. Prednisone is dosed at bedtime. This dosing schedule is also 
referred to as reverse circadian dosing. Some workers advocate dosing hydrocortisone and 
cortisone acetate 3 times a day citing more complete suppression of adrenal androgen 
synthesis, however, compliance becomes more difficult as the number of daily doses 
increases (Speiser et al., 2010; Newell-Price et al., 2008). 
In patients with classic CAH, hydrocortisone doses may be need to be raised somewhat to 
suppress progesterone prior to attempting conception, such that a proliferative 
endometrium may develop, followed by a secretory endometrium in an orderly sequence 
which will allow implantation to occur. There is no contraindication to breast feeding for 
women on hydrocortisone or cortisone acetate replacement. 
Dexamethasone treatment of mothers to prevent ambiguous external genitalia in the 
neonate is not recommended outside of well designed IRB-approved clinical trials. 
2.2 Mineralocorticoid replacement: Rationale, current dosing considerations and 
benefits 
In patients with severe, salt-wasting forms of classical CAH e.g. salt-wasting 21-hydroxylase 
deficiency and Visser-Cost syndrome mineralocorticoid replacement is essential in infants 
and young children as well as most adults. Some older children, adolescents, and adults can 
manage without supplemental mineralocorticoid if they maintain a high salt intake (Antal & 
Zhou, 2009). Even in some non-salt wasting forms of CAH there is, at least, mildly impaired 
aldosterone synthesis. It is recognized that in such patients mineralocorticoid replacement, 
while not essential for survival, does have a glucocorticoid sparing effect, allowing for 
maintenance of blood pressure, normal serum electrolytes, and general well being with 
somewhat lower doses of glucocorticoids, thus reducing the risk for bone loss, 
hyperglycemia, muscle weakness, and affective disturbances. Normalization of the plasma 
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renin activity (PRA) may be used as a barometer for adequate mineralocorticoid 
replacement. Usual adult mineralocorticoid replacement is with fludrocortisones 0.05- 0.15 
mg daily. 
2.3 Sick day and stress dose adjustments of glucocorticoids and mineralocorticoids 
Stress adjustments of glucocorticoids in CAH are similar to those in adrenal insufficiency. 
Mild stresses such as upper respiratory infections, minor injuries, and minor surgery require 
a doubling of the dose for 1-3 days. More serious stresses e.g. pneumonia, major fractures, 
or major surgery will require full stress doses of glucocorticoid e.g. 50-100 mg of 
hydrocortisone by intravenous piggyback or continuous infusion every 6-8 hours. As with 
daily maintenance doses of glucocorticoids for adrenal insufficiency, stress glucocorticoid 
dosage recommendations have fallen for CAH as well. There is now the realization that 
vascular tone, normalization of serum sodium, and prevention of hypoglycemia in ill and 
critically CAH patients can be achieved and maintained with significantly lower doses of 
glucocorticoid then previously prescribed. The current practice reduces the risk of inducing 
severe hyperglycemia, hypokalemia, and affective changes (Speiser et al., 2010). Intravenous 
bolus (push) doses of glucocorticoids should be avoided as they have been reported to cause 
dysrhythmias (Fujimoto et al., 1990). 
Mineralocorticoid doses do not generally have to be increased for stress. On mild stress days 
patients can be instructed to increase their salt and water intake. On severe stress days the 
use of intravenous 5% dextrose in 0.9 normal saline at about 3 liters/day in combination 
with high dose hydrocortisone, which has some mineralocorticoid activity at high serum 
levels, and will bind as an agonist to mineralocorticoid receptors, will provide adequate 
electrolyte and water homeostasis. Nevertheless, if hyponatremia or hypotension persist, 
fludrocortisone should be initiated or its dosage should be raised. (Connery & Coursin, 
2004; Riepe & Sippell, 2007). Stress glucocorticoid doses should be tapered as rapidly as the 
patient’s precipitating condition allows, monitoring serum glucose and electrolytes as well 
as blood pressure carefully (Connery & Cousin, 2004). 
Clearly, the treatment of the CAHs with glucocorticoids and mineralocorticoids has been 
one of the outstanding advances in modern medicine. It has been lifesaving for countless 
infants with classical CAH and has allowed for chromosomally congruent gender 
identification in many affected patients. It has ameliorated problems such as premature 
epiphysial closure with reduced adult height, hirsutism, acne, alopecia, menstrual 
disorders, and hypofertility/infertility. Associated polycystic ovaries often normalize 
their appearance on ultrasound.  
2.4 Limitations of glucocorticoid and mineralocorticoid therapy 
In the non-classical CAHs (NCAH), especially those with milder functional abnormalities of 
the affected enzyme or in some affected heterozygotes, it is often possible to normalize the 
production of adrenal androgens and steroid intermediates such as 17-hydroxyprogesterone, 
17-hydroxypregnenolone, and 11-deoxycortisol with low replacement doses. However, in the 
more severely affected patients production of androgens and intermediates may remain quite 
high with symptomatic implications (Merke & Bornstein, 2005).  
We are cautioned, appropriately, in these patients not to normalize androgen and 
intermediate production at the expense of treating with supraphysiologic glucocorticoid 
doses, which may cause bone loss, hyperglycemia, weight gain, and other more subtle 
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features of hypercortisolism. We are left, in these patients, to treat the remaining 
hyperandrogenism with androgen receptor blockers, e.g. spironolactone, which also reduces 
ovarian/adrenal androgen production (Merke & Bornstein, 2005; Merke, 2008).  
Oral contraceptives are frequently prescribed as adjunctive treatment to suppress associated 
ovarian hyperandrogenism and to impose a regular menstrual cycle (Merke, 2008). Recently, 
inhibitors of 5ǂ-reductase, finasteride and dutasteride, have been utilized to reduce the 
conversion of testosterone to dihydrotestosterone, the steroid compound most directly 
responsible for acne, alopecia, and hirsutism. Of the two medications, dutasteride is the 
more effective because it inhibits both forms of the enzyme (Choi et al., 2010). Additional 
strategies include the use of electrolysis for permanent removal of unwanted hair, laser for 
semi-permanent hair removal, depilatories for temporary hair removal, cosmetic bleaching 
of hair, benzoyl peroxide and retinoic acid derivatives for acne control and tetracyline, and 
its derivatives for suppression of Propionibacterium acnes in acne. 
3. The concept of insulin resistance in congenital adrenal hyperplasia 
3.1 Similarities to and overlap with polycystic ovarian syndrome 
Clinically, the features of the non-classical adrenal hyperplasias (NCAH’s) are:  
 premature adrenarche 
 menstrual irregularity 
 hypofertility/infertility 
 acne 
 hirsutism 
 alopecia 
 central adiposity 
 acanthosis nigricans 
 skin tags 
 increased risk of Type 2 diabetes mellitus (T2DM) 
 polycystic ovaries 
These are nearly identical with those of polycystic ovarian syndrome (PCOS) (Pall et al., 
2010). PCOS, which so closely resembles NCAH, is universally recognized to be associated 
with insulin resistance and is reported to be responsive to the insulin sensitizers metformin 
(Franks, 2011; Ladson et al., 2011) , troglitazone, rosiglitazone and pioglitazone (Franks, 
2011). One report (Paoletti et al., 1996) showed that many patients with PCOS responded to 
the dopamine receptor agonist, cabergoline, a compound which is now used in the 
treatment of T2DM. Given the multitude of similarities between PCOS and NCAH it seemed 
reasonable to believe that NCAH patients, like PCOS patients might be insulin resistant 
3.2 Possible mechanisms of insulin resistance in cah 
Review of studies linking CAH with insulin resistance and those showing 
biochemical/phenotypic amelioration with interventions that reduce insulin resistance 
invites the question - by what mechanism(s) do insulin resistance/hyperinsulinemia affect 
the expression of CAH?  
It is known that many factors affect the expression of both normal and mutant genes-the levels 
of transcription, translation, and post-translational gene product function. The nuclear 
transcription factor, peroxisome proliferator-activated receptor gamma (PPAR-Ǆ) affects the 
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expression of a wide variety of genes. PPAR-Ǆ is found in both the corticotrophs of the anterior 
pituitary and the adrenal cortex (Mannelli et al., 2010). Short, interfering RNA’s (siRNA’s) can 
silence transcription of normal or mutant genes as reported by Inoue et al., 2006.  
Hyperinsulinemia increases the biosynthesis of androgen by the adrenal cortex as reported 
by Arslanian et al (2002). This is partially due to an insulin-induced, post-translational 
hyperphosphorylation of P450c17ǂ, resulting in an increase in its 17,20 lyase activity in both 
adrenals and ovaries, thus magnifying the effect of any distal, adrenal steroidogenic defect.  
Kelly et al reported that steroidogenic factor-1 (SF-1) activity is upregulated in vitro by insulin 
in the presence of forskolin (a functional analog of ACTH) in this setting. Increased SF-1 
synthesis, as well as increased binding of SF-1 to its response element, resulted in increased 
transcription of CYP17 causing increased adrenal androgen synthesis in both normal, human 
adrenocortical tissue and in cultures of the adrenocortical tumor line H-295. In these same two 
in vitro systems insulin inhibited the forskolin stimulated synthesis of the transcription factor 
nur77, an action that results in decreased transcription of CYP21 mRNA, further directing 
adrenal steroidogenesis toward androgen vs cortisol biosynthesis. Thus, hyperinsulinemia 
would worsen the phenotypic/biochemical expression of 21-hydroxylase deficiency as well as 
magnify any other deficiencies of adrenal steroidogenic enzymes (Kelly et al., 2004). 
3.3 Review of studies demonstrating insulin resistance in congenital adrenal 
hyperplasia 
3.3.1 Hyperandrogenemia as a general accompaniment of the insulin-resistant state, 
type 2 diabetes mellitus 
Andersson et al. reported that women with T2DM had significantly higher plasma insulin 
concentrations, lower sex hormone binding globulin (SHBG), and higher circulating free 
testosterone levels than did BMI and gender matched controls. Men with T2DM had 
significantly lower total serum testosterone than a matched group of non-diabetic men, but 
no significant difference in their circulating free testosterone levels. They concluded that 
women with T2DM were relatively hyperandrogenemic and men with T2DM were 
normoandrogenic (Andersson et al., 1994). 
We noted (Sacerdote et al., 1994, 1995) that both hyperinsulinemia and hyperandrogenemia 
will suppress SHBG, resulting in lower total serum testosterone in both men and women. 
We added that other androgens, not measured in their study, e.g. androstenedione and 
DHEA might be contributing to the lowering of SHBG in both sexes. We reported that all 66 
of our consecutive, non-selected, type 2 diabetic patients (60 men and 6 women aged 29-89), 
had evidence of adrenal hyperandrogenemia as evidenced by elevated basal or cosyntropin-
stimulated serum androstenedione, DHEA, DHEA-S, free testosterone, or adrenal steroid 
intermediates eg 17-hydroxyprogesterone. In our series, the most frequent steroid elevations 
were of 17-OH-progesterone and 17-OH-pregnenolone, but we also reported glucocorticoid-
suppressible elevations of 11-deoxycortisol, and deoxycorticosterone (DOC). In addition, we 
reported glucocorticoid-reversible depressions of SHBG. Both Andersson’s study 
(Andersson et al., 1994) and ours noted an association between hyperandrogenism and Type 
2 DM-an insulin-resistant state. 
3.3.2 Non-classical 21-hydroxylase deficiency 
Speiser et al. reported insulin resistance in six women with untreated non-classical 21-
hydroxylase deficiency using a tolbutamide-modified, frequently-sampled intravenous 
glucose tolerance test (Speiser et al., 1992). These findings of Speiser’s were confirmed in 18 
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untreated women with non-classical 21-hydroxylase deficiency using the HOMA-IR (Saygili 
et al., 2005). Singer et al. reported persistence of insulin resistance in a patient with non-
classical 21-hydroxylase deficiency after normalization of her serum androgens with 
glucocorticoid, indicating that the hyperandrogenism was not contributing to the insulin 
resistance or, alternatively, that any insulin resistance due to hyperandrogenemia was 
replaced by insulin resistance due to glucocorticoid (Singer et al., 1989). Kroese et al. 
compared 12 glucocorticoid –treated adult patients with non-classical CAH with 12 controls 
determining insulin sensitivity by euglycemic clamp and oral glucose tolerance testing. 
CAH patients were insulin resistant compared with controls. Treatment with pioglitazone 
45 mg improved insulin sensitivity and lowered blood pressure in CAH patients (Kroese et 
al., 2009). In a study of 203 patients with CAH, 199 of whom had 21-hydroxylase deficiency, 
in the care of specialized endocrine centers across the United Kingdom National Health 
Service, it was found that 41% were obese and 29% were insulin resistant (Arit et al., 2010). 
Pall et al. reported that insulin sensitivity in women with non-classical 21-hydroxylase 
deficiency was indistinguishable from that of lean women with PCOS (Pall et al., 2010). In a 
meta-analysis it was concluded that NCAH was associated with increased fat mass, BMI, 
insulin resistance, and the metabolic syndrome (Mooij et al., 2010). 
3.3.3 Classical 21-hydroxylase deficiency 
Charmandari et al. reported that that, compared to children without classical CAH (n=28), 
children with classical 21-hydroxylase deficiency (n=16), both salt-wasters (n=12) and those 
with the simple virilizing phenotype (n=4) had significantly more insulin resistance as 
assessed by HOMA-IR as well as significantly higher serum leptin levels (Charmandari et al., 
2002). Zhang et al. reported that, compared with matched controls, 30 young adult women 
with classical, simple virilizing 21-hydroxylase deficiency (not on glucocorticoid treatment) 
had significantly higher BMI, 2-hour post-load plasma glucose, serum triglycerides, fasting 
insulin, and HOMA-IR as well as lower serum HDL. Serum adiponectin (considered a marker 
for insulin sensitivity) was markedly lower in the CAH patients. Linear regression analyses 
revealed that higher serum testosterone concentrations were significantly, positively correlated 
with metabolic disorder indices and negatively correlated with serum adiponectin 
concentration (Zhang et al., 2010). Zimmerman et al. studied 27 patients with classical 21-
hydroxylase deficiency, aged 4-31 on glucocorticoid replacement and a like number of sex, 
age, and BMI matched controls. They found that LDL, fasting serum glucose, insulin, and 
HOMA-IR were significantly higher in the patients with classical 21-hydroxylase deficiency, 
while HDL was significantly lower. These authors attributed the adverse metabolic changes to 
glucocorticoid therapy as HOMA-IR showed a significant positive correlation with 
hydrocortisone dose (Zimmerman et al., 2010). Atabek et al. reported a 5 year old girl with 
female pseudohermaphroditism due to classical 21-hydroxylase deficiency with insulin 
resistance and Turner’s syndrome. These authors noted an improvement in insulin sensitivity 
when their patient was treated for hyperandrogenemia with glucocorticoid (Atabek et al., 
2005). Ambroziak et al. reported that adult patients with classical 21-hydroxylase deficiency 
have obesity, hyperinsulinemia, insulin resistance, and hyperleptinemia more frequently than 
age/sex matched controls (Ambroziak et al., 2010). 
3.3.4 Non-classical 3-β-ol dehydrogenase deficiency 
Carbunaru et al. have reported that the hormonal phenotype of non-classic 3-ǃ-ol 
dehydrogenase deficiency in hyperandrogenemic females is associated with insulin-resistant 
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PCOS and is not a variant of genetic HSD3B2 deficiency (Carbunaru et al., 2004). This article is 
consistent with a publication by (Lutfallah et al., 2002) that proposed new hormonal criteria for 
the diagnosis of those patients with mutations in the Type II 3-beta-ol dehydrogenase exon. 
They noted that in the vast majority of patients who had been diagnosed with non-classic 3-ǃ-
ol dehydrogenase deficiency using criteria analogous to those used to diagnose non-classic 21-
hydroxylase deficiency no mutation could be found in the HSD3B exon. This, of course, does 
not exclude the possibility that these patients could harbor mutations in the extra-exonic 
portions of the gene, for example in the promoter region, as has recently been reported in some 
patients with 21-hydroxylase deficiency (Araújo et al., 2007). In addition, other factors may 
affect the transcription, translation, or post-translation activity of steroidogenic genes. For 
example, insulin up-regulates the transcription of 17-ǂ-hydroxylase and downregulates the 
transcription of 21-hydroxylase (Kelly et al., 2004), while it also causes a post-translational 
hyperphosphorylation of P450c17ǂ resulting in a gain of function in its 17,20 lyase activity in 
both the ovaries and the adrenal cortex which, in turn, magnifies the effects of any distal 
adrenal steroidogenic enzyme defects and potentiates the effect of LH on ovarian androgen 
synthesis (Arslanian et al., 2002). Genes with perfectly normal nucleotide sequences may have 
their transcription blocked by excessive methylation or aberrant histone acetylation. 
3.3.5 Other forms of non-classical CAH associated with insulin resistance 
Our reports on adrenal hyperandrogenemia and T2DM (Sacerdote et al., 1994, 1995) clearly 
included patients with 3-ǃ-ol dehydrogenase deficiency and aldosterone synthase deficiency 
and some who were not definitively characterized, but who had glucocorticoid-suppressible 
elevations of androstenedione, DHEA, DHEA-S, and free/total serum testosterone as well 
as glucocrticoid normalizable depressions of SHBG. In Arit’s study four of 203 patients with 
CAH had forms of NCAH other than 21-hydroxylase deficiency (Arit et al., 2010). We 
studied 26 consecutive, non-selected psychiatric patients taking classical anti-psychotic 
agents, atypical anti-psychotic agents, and/or valproate and we noted that all 26 had 
adrenal hyperandrogenemia; 2 had biochemical evidence of 21-hydroxylase deficiency, 8 of 
3-ǃ-ol–dehydrogenase deficiency, four of 11-hydroxylase deficiency, and two of aldosterone 
synthase deficiency (Bahtiyar et al., 2007). All of the above psychotropic agents cause insulin 
resistance and 10/10 patients who took an insulin sensitizer normalized biochemically.  
3.3.6 Studies linking insulin resistance with forms of classical CAH other than 21-
hydroxylase deficiency 
Charmandari et al.’s series reporting elevated serum leptin levels and insulin resistance in 
children with classic CAH included 2 patients with 11-hydroxylase deficiency (Charmandari 
et al., 2002). 
4. Studies showing utility of insulin sensitization in adrenal hyperplasia 
4.1 Metformin and/or thiazolidinediones in the non-classical adrenal hyperplasias 
In 2000 we reported that metformin alone or, in some patients, with the first thiazolidinedione 
(TZD) troglitazone, normalized elevated serum steroid metabolites and ameliorated acne, 
alopecia, and hirsutism in patients with T2DM and non-classical forms of 21-hydroxylase 
deficiency, 11-hydroxylase deficiency, 3-ǃ-ol dehydrogenase deficiency, and aldosterone 
synthase deficiency (Osehobo et al., 2000). In 2003 we reported that the biochemical 
/phenotypic expression of NCAH, including 21-hydroxylase deficiency, 3-ǃ-ol dehydrogenase 
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deficiency, 11-hydroxylase deficiency, and aldosterone synthase deficiency could be 
normalized with rosiglitazone, an example of which may be seen in (Sacerdote et al., 2003) 
[Figure 1]. In 2004 we reported that the biochemical/phenotypic expression of NCAH is 
correctible with pioglitazone (Sacerdote et al., 2004). An example of the combined effect of 
metformin and pioglitazone as compared with standard treatment in a patient with non-
classical 21-hydroxylase deficiency is shown in Figure 2. Note that the suppression of 17-OH-
progesterone is more complete with the combined insulin sensitizers and even with metformin   
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Fig. 1. Response of a 43-year-old Male’s 17-OHP (ng/dl) to rosiglitazone 4mg twice daily. 
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Fig. 2. Response of a 57-year-old Female’s 17-OHP (ng/dl) to cortisone acetate, metformin, 
& pioglitazone 
Rosiglitazone Baseline 
Baseline Cortisone Metformin Met./piogli. 
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monotherapy than it is with standard treatment. Arslanian et al. reported that metformin 
treatment in obese teens with PCOS and impaired glucose tolerance (IGT) ameliorated their 
exaggerated adrenal response to ACTH with concomitant reduction in insulinemia/insulin 
resistance (Arslanian et al., 2002). The time course of biochemical improvement in NCAH 
patients treated with metformin or a TZD is quite rapid-within 24 hours of initiating therapy. 
4.1.2 Metformin or rosiglitazone in the psychotropic/valproate-induced adrenal 
hyperplasias 
Many medications exert an endocrine disrupter effect by virtue of directly causing insulin 
resistance or indirectly causing insulin resistance by increasing appetite with resultant 
weight gain. Among these are both classical and atypical anti-psychotic drugs, valproate, 
which has also been associated with PCOS (Bilo & Meo, 2008), nucleoside analogs, and 
protease inhibitors. The latter two groups of anti-retroviral drugs have also been 
associated with adrenal hyperplasia (Sacerdote, 2006). In our study we found that 
metformin corrected adrenal hyperandrogenism in 8/8 patients and rosiglitazone 
corrected adrenal hyperandrogenism in 2/2 patients on anti-psychotic drugs and/or 
valproate (Bahtiyar, 2007). (Figures 3 and 4).  
 
 
Fig. 3. Effect of metformin on elevated steroid metabolites (Represented a % of baseline). 
lightly shaded bars are baselines; darkly shaded bars are on metformin treatment.  
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Fig. 4. Effect of rosiglitazone on elevated baseline 11-deoxycortisol level (mg/dl) 
4.1.3 Metformin to treat classical 21-hydroxylase deficiency 
Because the classical CAH’s are much less common than the non-classical forms and also 
because we are adult endocrinologists and many adolescent/adult classical CAH patients 
tend to remain in the care of their pediatric endocrinologists, it was a number of years 
from when we first conceived the notion of treating classical CAH with insulin sensitizers 
until we were able to participate in the treatment of a classical CAH patient through the 
collaboration of a pediatric endocrine colleague, Dr. Levon Agdere (Mapas-Dimaya et al, 
2008). Our patient was a 17-year-old female who was born with ambiguous genitalia and 
developed severe hyponatremia and dehydration in the nursery, where she was correctly 
diagnosed and appropriately treated. At one year of age she underwent clitoroplasty. 
During 4 years of treatment with her previous pediatric endocrinologist her vital signs 
and electrolytes remained normal and her height was 142.33 cm which was below the 
third percentile for her age. A bone age performed at 15.5 years was slightly advanced at 
16.0 years. Since age 13 she had been on hydrocortisone 30 mg/day given in two divided 
reverse circadian doses (10 mg in am and 20 mg in pm) as well as fludrocortisones 0.05 
mg daily. Medication compliance was verified with pill counts and refill data. On this 
regimen she continued to have normal serum electrolytes, glucose, blood pressure, and 
external genitals, but she noted truncal obesity, hirsutism, acanthosis nigricans, and 
amenorrhea. Her 17-OH-progesterone remained persistently elevated at 3410 ng/dl (20-
500) as was her serum total testosterone at 326 ng/dl (15-70). She was maintained on her 
glucocorticoid/ mineralocorticoid regime and after obtaining the informed consent of the 
patient and her parents metformin 500 mg orally after breakfast and supper was added. 
As seen in Figures 5 and 6 both steroid metabolites fell by about 50% on this combined 
regimen to 1539 ng/dl and 163 ng/dl respectively. Her amenorrhea resolved and her 
 Baseline 
 Rosiglitazone 
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hirsutism improved. Our long term intention was to gradually up-titrate her metformin 
dose and, if necessary, add a TZD until levels of both steroid metabolites normalized and 
then begin a cautious tapering of her glucocorticoid dosage, however, our patient 
declared herself satisfied with her initial improvement and declined to undergo further 
adjustments in her treatment or further testing. 
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Fig. 5. Effect of metformin addition on 17-OHP (ng/dl) in a patient with classical, salt-
wasting 21-hydroxylase deficiency  
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Fig. 6. Effect of metformin on serum total testosterone (ng/dl) in classical 21-hydroxylase 
deficiency 
4.1.4 Limitations of metformin and thiazolidinediones in the treatment of CAH 
Although metformin has been shown to be effective as monotherapy or with a TZD for 
several forms of NCAH and as an adjunctive therapy for classical, salt-losing 21-
hydroxylase deficiency, it is currently unknown whether metformin would be an effective 
treatment for classical, simple virilizing 21-hydroxylase deficiency or for any other form of 
classical CAH. We do not know if metformin monotherapy or combination therapy with a 
TZD could ultimately replace glucocorticoid completely in any of the classical CAH’s.  
In women with PCOS, metformin has been shown, not only to be safe to use throughout 
pregnancy, but to reduce hyperinsulinemia, weight gain, gestational diabetes mellitus (GDM), 
and spontaneous abortion (Glueck et al., 2004; Jakubowicz et al., 2002). Metformin is generally 
Baseline Metformin 
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considered safe in both gestational and pre-gestational diabetes mellitus and GDM as it is U.S. 
F.D.A. Class B. There is also evidence that is safe in nursing mothers (Feig et al., 2007). 
Many patients are unable to tolerate the gastrointestinal side effects of metformin, 
particularly at maximally effective doses. The tolerability of metformin may be increased by 
a number of different strategies: 
 Administration after meals 
 Gradual dose titration to allow for adaptation to the drug 
 Use of extended release preparations which are better tolerated than the short acting 
tablets 
 Use of liquid preparations (RiometR) 
 Use of extended release polymer form (GlumetzaR) 
 Addition of an H2 blocker or proton pump inhibitor 
Metformin should be avoided or very closely monitored in patients with Stage III or worse 
chronic kidney disease, patients with serious bacterial infections, and for at least two days 
before and after administration of iodinated intravenous radiographic contrast materials or 
before and after major surgery, so as not to increase the risk of lactic acidosis. There is little 
risk of serious hypoglycemia with metformin monotherapy, but mild hypoglycemia may 
occur if meals are skipped, skimped, or delayed. Serum vitamin B12 and folate levels should 
be checked periodically in patients using metformin as deficiencies may develop resulting in 
elevated serum homocysteine levels and peripheral neuropathy, especially in patients with 
comorbid diabetes. 
TZD’s have been shown to ameliorate the biochemical/phenotypic findings in most forms 
of NCAH. To date there are no studies or case reports where they have been used to treat 
classic CAH. Common side effects of this class of drugs include weight gain, increased 
subcutaneous fat mass, and edema. Less common, but more serious adverse effects of this 
class include: congestive heart failure, bone loss, fracture, and bladder carcinoma. With 
regard to the latter, we have unpublished data in one diabetic patient suggesting 
reversibility of pre-macroscopic bladder carcinoma after withdrawal of TZD’s.  
TZD-mediated edema appears to respond well to thiazides, spironolactone, triamterene, and, 
in our experience, to the renin antagonist aliskerin. It is somewhat resistant to loop diuretics 
such as furosemide. Data from the PROactive study (Dormandy J et al, 2009) indicate that 
congestive heart failure developing in patients taking TZD’s is no more treatment refractory or 
lethal than that occurring in Type 2 diabetic patients not using TZD’s.  
To date there are no randomized control trials (RCT’s) on treatment or prevention of TZD-
associated bone loss, although in the authors’ experience osteopenic/osteoporotic TZD 
users respond satisfactorily to standard treatments.  
The use of rosiglitazone in the treatment of T2DM has been questioned as a result of a meta-
analysis published by Nissen and Wolski (Nissen & Wolski, 2007) reporting a “signal” of 
increased risk of myocardial infarction in rosiglitazone users compared to Type 2 diabetics 
not using this drug. This report, while controversial, has resulted in rosiglitazone being 
banned in the EU and severely restricted in the US. 
Although many women have become pregnant while taking TZD’s either for T2DM or for 
PCOS and there have not been reports of an adverse effect upon the pregnancies, there have 
been no published reports of their use beyond the first trimester. It is recommended that 
TZD’s be stopped when pregnancy is suspected or confirmed. TZD monotherapy does not 
result in hypoglycemia.  
www.intechopen.com
Management Approaches to Congenital Adrenal  
Hyperplasia in Adolescents and Adults; Latest Therapeutic Developments 
 
77 
5. Utility of lifestyle interventions in the treatment of non-classic aldosterone 
synthase deficiency 
We first reported the non-classic form of aldosterone synthase deficiency in 1999 (Osehobo 
& Sacerdote, 1999). Before this only the rare, severe salt-wasting form of this disorder 
(Visser-Cost syndrome) was known. Subsequently we reported that the 
biochemical/phenotypic expression of non-classic aldosterone synthase deficiency could be 
normalized by weight loss and exercise, two interventions that reduce insulin resistance in 
two women with this disorder (Sacerdote, 2002). (Figure 7). 
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Fig. 7. Percent changes with weight loss and exercise in two women with non-classic 
aldosterone synthase deficiency. Light bars are baselines, shaded bars are post-treatment 
6. Utility of gastric bypass surgery in the treatment of non-classical 11-
hydroxylase deficiency 
Recently we found that a patient of ours with non-classical 11-hydroxylase deficiency, 
T2DM, and morbid obesity who underwent Roux en Y gastric bypass surgery normalized 
her serum 11-deoxycortisol as effectively with surgery as she previously had done with 
metformin plus pioglitazone (Figure 8). Roux-en-Y gastric bypass has previously been 
reported to ameliorate PCOS (Eid et al., 2005).  
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Fig. 8. Response of Patient’s 11-deoxycortisol (ng/dl) to Roux-en-Y Gastric Bypass. 
(Normal < 51) 
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7. Future directions 
7.1 Large randomized control trials of metformin/thiazolidinediones in classical CAH 
While the therapeutic efficacy of metformin and TZD’s in NCAH is fairly well established, 
we only have a single case report of metformin being used in classical CAH. We do not 
know whether metformin and/or TZD’s can completely normalize serum levels of 17-
hydroxyprogesterone and testosterone when added to steroid “replacement” , nor is it yet 
known whether metformin/TZD could actually render steroid replacement unnecessary in 
treating classical salt-wasting 21-hydroxylase deficiency. We have no data as to whether 
these insulin sensitizers have any efficacy in the treatment of any other form of classical 
CAH. Well designed RCT’s will be necessary to answer these important questions.  
7.2 Other insulin sensitizers in congenital adrenal hyperplasia 
7.2.1 Dopamine agonist pilot studies 
Increasing dopaminergic tone has been reported to have an insulin sensitizing effect (Pijl et 
al., 2000; Scranton R et al., 2010) and dopamine receptor agonists e.g. bromocriptine are 
approved for the treatment of T2DM and PCOS, while dopamine receptor antagonists are 
known to be associated with insulin` resistance and increase the risk for development of 
glucose intolerance. Cabergoline is used successfully in treating PCOS (Paoletti et al., 1996) 
as is bromocriptine (Spruce et al., 1984). On this basis we might predict that CAH might 
improve if treated with dopamine agonists. 
7.2.2 Vitamin D pilot studies 
Studies in animals show that vitamin D deficiency is associated with impaired insulin 
sensitivity, and that insulin secretion can be increased by vitamin D supplementation (Tai et 
al., 2008). Epidemiological studies in man show associations between low vitamin D levels 
and glucose intolerance (Nunlee et al., 2011). Pittas et al. systematically reviewed the 
intervention trial evidence for the role of vitamin D and/or calcium in the prevention of 
metabolic syndrome and T2DM (Pittas et al., 2007). On the basis of evidence from small 
intervention trials or post hoc analyses of trials, they concluded that it was difficult to be 
definite whether or not vitamin D and/or calcium were important in the prevention of 
T2DM, and that effects might only be manifest in people who were particularly at risk of 
T2DM. Other authors have implicated Vitamin D deficiency/insufficiency in the 
pathogenesis of insulin resistance, pre-diabetes, T2DM, and PCOS (Cavalier et al., 2011; 
Wehr et al., 2011). Rashidi et al reported that supplementation of just 400 IU daily of 
Vitamin D increased the ovulation rate significantly when added to 1500 mg/day of 
metformin (Rashidi et al., 2009). We have just begun to collect Vitamin D data on some of 
our NCAH patients and the first three have 25-OH-Vitamin D levels ranging from 18-19 ng 
/dl. These include one patient with 21-hydroxylase deficiency, 1 with p450-oxidoreductase 
deficiency, and one male patient with glucocorticoid-suppressible elevated DHEA-S. Given 
this data it may be reasonable to embark on pilot studies utilizing Vitamin D as 
monotherapy or in combination with other agents in the treatment of NCAH. 
7.2.3 Bile acid binding pilot studies 
The bile acid binding resin, colesevelam, has recently been approved for the treatment of 
T2DM in addition to its original indication for the treatment of hypercholesterolemia. It 
improves insulin resistance in a diet-induced rodent model by increasing the release of GLP-
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1 (Zhang et al., 2010). In a pilot study Schwartz et al. reported that in patients with T2DM 
colesevelam had no effect on peripheral insulin sensitivity or glucose absorption, but may 
improve glycemic control by improving whole body insulin sensitivity. Pilot studies with 
this agent in both PCOS and NCAH might be warranted due to its insulin sensitizing effects 
(Schwartz et al., 2010). 
7.2.4 GLP-1 agonist pilot studies 
The GLP-1 agonists exenatide and liraglutide are both associated with weight loss, the latter 
somewhat more so. The weight loss, particularly that of visceral and non-adipose tissue fat, 
is associated with an improvement in insulin sensitivity (Liu et al., 2010; Defronzo et al., 
2010). Exenatide has been reported to ameliorate PCOS (Elkind-Hirsch et al., 2008). 
Therefore, it seems reasonable to plan pilot studies with these agents in CAH. 
7.2.5 Orlistat pilot studies 
The fat absorption blocking agent orlistat is approved as a weight loss aid when combined 
with diet and exercise in the U.S. in both a 60 gm over the counter form and a prescription 
only 120 mg form. In Canada it is approved for the treatment of T2DM. Panidis et al. 
reported that orlistat in combination with diet produced significant weight loss and 
improvement in insulin sensitivity in obese women, with or without PCOS. In addition, 
serum testosterone levels were significantly improved in women with PCOS (Panidis et 
al., 2008). Based on these data pilot studies of orlistat in NCAH should be performed. 
7.2.6 Cannabinoid receptor blockade pilot studies 
Stimulation of the CB-1 cannabinoid receptor has known orexic and euphoric effects, while 
its blockade with rimonabant has been associated with anorexic and dysphoric effects and 
results in weight loss, reduced insulin resistance, and improvements in glycemia and serum 
lipid levels (Migrenne et al., 2009) and has shown efficacy in PCOS patients (Sathyapalan et 
al., 2008). Rimonabant was not approved in the U.S. and its approval was withdrawn in 
Europe because of a higher suicide risk due, presumably, to its dysphoric effect. The 
risk/benefit ratio of this class of agents might be improved by better patient selection, 
selective co-administration of an anti-depressant, treatment of hyperhomocysteinemia 
(which may play a role in depression, or the development of selective cannabinoid receptor 
modulators, possessing the beneficial anorexic effect of the class without causing dysphoria. 
The selective estrogen receptor modulators (SERM’s), now in widespread clinical use, 
provide a model for such future development. Since these agents reduce insulin resistance, 
we might predict that they could ameliorate CAH. 
7.2.7 Continuous positive airway pressure (CPAP) in CAH patients with obstructive 
sleep apnea (OSA) 
Many, if not most, insulin resistant people have OSA (Vgontzas et al., 2005). Treatment with 
CPAP has been shown to improve insulin sensitivity in women with PCOS (Tasali et al., 
2011). Vgontzas et al have reported that the inflammatory cytokines, TNF-ǂ and IL-6 are 
elevated in patients with OSA, independently of obesity and that visceral fat was the 
primary parameter linked with OSA (Vgontzas et al., 2005). The fact that they found that 
OSA was more common in women with PCOS suggested a pathogenetic role of insulin 
resistance in OSA. The beneficial effect of a cytokine antagonist on excessive daytime 
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sleepiness in obese, male apneics and on sleep disordered breathing in a general, random 
sample supports the hypothesis that cytokines and associated insulin resistance are 
mediators of excessive daytime sleepiness and OSA. Hamada et al have reported that with 
nasal CPAP in a CAH patient with OSA they were able to reduce the maintenance 
glucocorticoid dosage (Hamada et al., 2011). CAH patients who have clinical features 
consistent with OSA, might benefit from undergoing a sleep study followed by a CPAP 
titration study if the initial sleep study is diagnostic. Alternatively, inhibitors of TNF-ǂ and 
IL-6 might be useful adjuncts in the treatment of CAH. 
7.2.8 Curcumin 
Curcumin is a component of the popular spice, turmeric. It has been reported to decrease 
levels of the inflammatory cytokine, TNF-ǂ, which, in turn, downregulates the transcription 
factor PPAR-Ǆ. Administration of curcumin results in up-regulation of PPAR-Ǆ m-RNA and 
protein, which we would predict would improve insulin sensitivity (Gosh et al., 2009). Pilot 
studies with curcumin in CAH patients, would, therefore, be of interest given the absence of 
any known adverse effects. Other spices, herbs, and supplements known or suspected to 
have insulin sensitizing effects would also be worth exploring in CAH. 
7.2.9 L-carnitine 
L-carnitine has been reported to reduce insulin resistance, when added to orlistat, 
significantly more than orlistat alone (Derosa et al., 2010). For this reason, a pilot study 
treating CAH patients with this supplement would be of value. 
7.3 Other insulin-lowering agents 
7.3.1 Somatostatin analogs 
Somatostatin and its analogs- octreotide, octreotide LAR, and lanreotide partially suppress 
insulin secretion; reduction of hyperinsulinemia by this means could result in amelioration 
of both PCOS and CAH. Gambineri’s group reported that octreotide-LAR improved the 
ovulation rate and hirsutism and showed nearly significant trends toward greater 
reductions in serum testosterone and androstenedione compared with placebo in dieting 
women with abdominal obesity and PCOS (Gambineri et al., 2005). Pilot studies of these 
drugs in these two conditions, would, therefore, be of interest. Because they reduce the 
secretion of growth hormone they would not be suitable for use in children or adolescents.  
7.3.2 Diazoxide and phenytoin 
These drugs both decrease insulin secretion and have been reported to be helpful in treating 
some PCOS patients (Bercovici et al., 1996; Verrotti et al., 2011). On this basis we might predict 
a response in CAH patients as well. In designing pilot studies with these agents patients with 
pre-diabetes or low bone density should probably be excluded due to the diabetogenic 
potential of both drugs and the accelerated Vitamin D clearance attributed to the latter. 
7.4 Gene therapy 
Gene therapy, wherein the defective gene is supplemented with a functional one should, 
theoretically, be the ideal therapy for every form of CAH, with the possible exception of 
non-classical 3-ǃ-ol dehydrogenase deficiency, for which no mutation in the exon has been 
identified (Carbunaru et al., 2004). 
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7.4.1 Adenoviruses 
Adenoviruses are adrenocorticotropic, making them a good vector in which to deliver 
functional genes. 21-hydroxylase genes have been delivered in adenoviruses by intra-
adrenal injection in 21-hydroxylase-deficient mice and bovine adrenocortical cells have 
shown functional and morphological changes in the adrenal cortices after transfection 
with recombinant adenovirus (Loechner et al., 2010). While encouraging, overall safety 
and specificity in targeting the adrenal cortex remains to be established. There may be a 
need to develop new vectors (viral or non-viral) to optimize the specificity and efficiency 
of adrenal gene transfer and ensure long term DNA integration. Recently, other 
recombinant viruses, e.g. retrovirus, lentivirus, adeno-associated virus, and Herpes 
simplex have been successfully used as gene vectors. Non-viral gene delivery methods 
that use natural or synthetic compounds or physical forces to deliver DNA to the cell are 
now available. 
7.4.2 Adult stem cells 
Adult stem cells may be obtained from a variety of tissues and have been studied in several 
milieus, especially the hematopoietic system. Limiting factors with adult stem cells include: 
 Limited pluripotency 
 Difficulty of maintenance in vitro 
 HLA compatibility restraints on transplantation, thus requiring immunosuppression 
with its attendant risks, cost, and inconvenience 
Recent studies have described methods which are generally applicable for the preparation of 
induced pluripotent stem cells (IPSC’s) from various somatic cell lineages. Marrow-derived 
mesenchymal cells (MSC’s) are unique in that they are obtained from adults, yet are still 
pluripotent. MSC’s or IPSC’s obtained from CAH patients would harbor a genetic defect in 
steroidogenesis and, thus, would only be helpful as cellular vectors for gene therapy. 
Despite their shortcomings, the use of adult stem cells benefits from a longer investigational 
track record and avoids ongoing political issues with the use of fetal stem cells. Yazawa et 
al. have reported that human MSC’s transfected with SF-1, a transcription factor required for 
both adrenal and gonadal steroidogenesis, differentiate into cortisol producing cells rather 
than androgen producing cells when transplanted into mouse testis, while Gondo et al 
reported that such cells were ACTH-responsive (Yazawa et al., 2006; Gondo et al., 2004). 
Another approach is that of Hammer et al who characterized a subpopulation of adrenal 
cells that are typically dormant or undifferentiated. Stimulation of these cells to differentiate 
into mature adrenal cells is possible and studies aimed at collecting this quiescent 
population for differentiation/regeneration of adrenal tissue could be helpful in both CAH 
and adrenal insufficiency (Kim et al., 2007). 
7.4.3 Embryonic stem cells 
Embryonic stem cells (ESC’s) offer an approach that avoids many of the problems inherent 
with the use of adult stem cells. ESC’s harvested during the blastocyst stage are easier to 
culture in vitro and remain for longer periods in the pluripotent stage. ESC’s could be 
triggered to differentiate into regulated, steroidogenic cells using methodologies derived from 
adult stem cell studies. As with adult tissue transplants, HLA matching is needed and there is 
the potential for graft rejection and, therefore, the necessity of using immunosuppressive 
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therapy. The next generation of ESC’s could be so closely matched that post-transplantation 
immunosuppressive treatment would not be needed (Loechner et al., 2010). 
7.5 Corticotropin releasing hormone (CRH) antagonists 
Inhibition of CRH should dampen the secretion of ACTH, which should facilitate the 
normalization of adrenal androgen secretion with lower doses of glucocorticoid. Pre-clinical 
studies with the CRH antagonist alarmin demonstrated blockage of CRH-1 receptor-
induced increases, both in adrenal size and behavioral responses. CRH analogs with more 
extended action e.g. astressin inhibit ACTH release. CRH 9-41 reduces stress measures in 
sheep. Human CRH receptor antagonist trials demonstrated a reduction in CRH-associated 
signs of anxiety and depression. Since these studies have not unequivocally demonstrated 
reductions in CRH-induced ACTH secretion or an effect on cortisol secretion, their clinical 
relevance remains uncertain at present (Loechner et al., 2010). 
7.6 Inhibition of ACTH secretion/action 
The discovery of selective melanocortin receptor subtypes, eg MC2-R, for ACTH in the 
adrenal cortex affords the possibility of inhibition of ACTH action in the adrenal cortex with 
a diminution in adrenal androgen production. This approach could have a glucocorticoid 
sparing effect. Clinical trials will be important to assess the resilience of HPA reserve and 
the safety of this approach. 
Blockade of ACTH secretion is under investigation. In vitro studies showed that ACTH 
release from corticotrophs is coupled with the dihydropyridine-sensitive subclass of 
voltage-dependent calcium channels Clinical trials in Cushing disease reported acute 
decreases in ACTH levels with calcium channel blockers such as nifedipine and amlodipine. 
A small trial reported similar magnitude plasma ACTH reductions in 13 children with either 
classic salt-wasting or simple, virilizing 21-hydroxylase deficiency. 
Other agents which may decrease ACTH secretion include the serotonin receptor blocker, 
cyproheptadine, the dopamine receptor agonist, cabergoline, and the GABA receptor 
inhibitor, valproate. These agents have been reported to be efficacious in both Cushing 
disease and Nelson’s syndrome, and for this reason, may prove to be helpful in CAH 
(Loechner et al., 2010). 
7.7 Newer glucocorticoid delivery strategies 
Studies of circadian cortisol delivery using either hydrocortisone infusions or modified 
release oral formulations demonstrate that these systems can better mimic physiologic 
cortisol rhythm, resulting in better glucocorticoid replacement and ACTH suppression in 
CAH patients. Continuous subcutaneous cortisol infusion (CSCI) has proven effective and 
well tolerated for over 4 years in a 14 year old CAH patient and resulted in a 50% reduction 
in daily cortisol dosage within the first 3 months of treatment (Loechner et al., 2010). Two 
glucocorticoid formulations that exploit the pharmacokinetic peak of once/day, dual-timed 
cortisol to mimic the diurnal variation peak of ACTH, facilitating more physiologic delivery 
of cortisol are currently being evaluated. Chronocort, one such preparation, seems promising. 
In a head to head study with Cortef dosed 3 times/day with a larger evening dose, it was 
reported that the Cortef regimen resulted in 3 distinct peaks, while a single daily peak at 
0600 was noted with bedtime dosing of Chronocort. At 0600 levels of 17-OH-progesterone, 
ACTH, and androstenedione were lower with Chronocort, however, afternoon androgen 
control was better with Cortef. 
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7.8 Aromatase inhibitors 
These agents will help block the conversion of androgens to estrogens and thus help block 
premature epiphysial closure in children and adolescents with CAH (Loechner et al., 2010). 
7.9 GnRH agonists with or without growth hormone 
As with central precocious puberty, GnRH agonist monotherapy or in combination with GH 
has been reported to improve the chances of reaching predicted adult height (PAH) in CAH 
patients with early puberty due to early maturation of the hypothalamic-pituitary-gonadal 
(HPG) axis. While GnRH agonists prevent premature epiphyseal closure, GH can prevent 
the stalling in vertical growth velocity that occurs otherwise when precocious puberty is 
either prevented or aborted (Loechner et al., 2010). 
8. Summary/conclusions 
In summary, a role for insulin resistance in the pathogenesis of NCAH may be suspected 
because of numerous similarities in the clinical expression of PCOS and NCAH. 
Confirmation of the presence of insulin resistance in CAH has been reported for: 
 Non-classical 21-hydroxylase deficiency 
 Non-classical 3-ǃ-ol dehydrogenase deficiency 
 Non-classical 11-hydroxylase deficiency 
 Classical simple virilizing 21-hydroxylase deficiency 
 Classical salt-wasting 21-hydroxylase deficiency 
 Classical 11-hydroxylase deficiency 
Metformin, troglitazone, rosiglitazone, and pioglitazone-all agents known to reduce insulin 
resistance and ameliorate PCOS have been shown to phenotypically/biochemically 
ameliorate: 
 Non-classical 21-hydroxylase deficiency 
 Non-classical 3-ǃ-ol dehydrogenase deficiency 
 Non-classical 11-hydroxylase deficiency 
 Non-classical aldosterone synthase deficiency 
 Classical salt-wasting 21-hydroxylase deficiency 
Weight loss by lifestyle modification (diet + exercise) has been shown to normalize DOC 
levels, the LH/FSH ratio and phenotypically ameliorate non-classical aldosterone synthase 
deficiency. Roux-en-Y gastric bypass has been shown to phenotypically/biochemically 
ameliorate non-classical 11-hydroxylase deficiency. 
ALL INSULIN SENSITIZING INTERVENTIONS THUS FAR INVESTIGATED 
AMELIORATE EVERY FORM OF CAH TESTED TO DATE. 
 While glucocorticoid/mineralocorticoid replacement/suppression has been 
spectacularly successful in the treatment of CAH and remains, for now, the gold 
standard for therapy of this family of disorders, there remain many patients for whom 
the goal of adequate androgen suppression, while avoiding the pitfalls of 
hypercortisolemia, remain elusive. Androgen receptor or 5-ǂ-reductase blockade may 
be added to blunt the clinical effects of inadequately suppressed adrenal androgen 
secretion. In the future glucocorticoid/ mineralocorticoid therapy may be further 
refined by the use of novel long acting and dual peak preparations of hydrocortisone 
and newer steroid delivery systems e.g. CSCI. Adrenal androgen secretion may be 
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further reduced in the future by means of CRH or ACTH blockade, while the 
combination of GnRH agonists with GH may help to more nearly achieve PAH. 
 The recognition that insulin resistance/hyperinsulinemia is a regular feature in CAH 
that contributes to its biochemical/phenotypic expression has led to the finding that 
metformin and/or TZD’s may replace standard therapy in NCAH and that metformin 
may be used, at least as adjunctive therapy, in classic, salt-wasting 21-hydroxylase 
deficiency. Exercise and weight loss have been shown to ameliorate non-classic 
aldosterone synthase deficiency, while Roux-en-Y gastric bypass can normalize the 
biochemical expression of non-classic 11-hydroxylase deficiency. Other therapies that 
decrease insulin levels, including those that have already shown efficacy in PCOS, seem 
likely to show therapeutic benefit in CAH. 
 In the future it is likely that there will be further refinements in steroid 
replacement/suppression, more widespread use of treatments to decrease 
hyperinsulinemia, and further progress in gene therapy. 
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